文献速递认知障碍与痴呆

抗胆碱能药物与AD生物标志物对认知正常老年人MCI发病的关联

Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults.
PubMed 文献 · Neurology · 2020-09-02

研究纳入688名认知正常老年人,随访10年,发现使用抗胆碱能药物者进展为轻度认知障碍的风险增加(HR 1.47),且与APOE ε4或CSF AD病理标志物存在显著交互作用,风险分别增至2.69倍和4.89倍。药物使用还预测记忆与语言下降更快。

要点

  • 抗胆碱能药物增加认知正常老年人进展为MCI的风险(HR 1.47)。
  • 携带APOE ε4或CSF AD病理者使用抗胆碱能药物风险更高(HR 2.69和4.89)。
  • 抗胆碱能药物与记忆和语言下降更快相关,AD风险因素加剧此效应。

核心结论

  • 抗胆碱能药物增加认知正常老年人进展为MCI和认知下降的风险,尤其在具有遗传或CSF AD病理风险因素者中效应更强。

研究设计与样本

  • 来自阿尔茨海默病神经影像学倡议的688名认知正常参与者,平均年龄73.5岁,49.6%女性,采用Cox回归和线性混合效应模型分析。

主要发现

  • aCH+者进展为MCI风险增加(HR 1.47,p=0.02)。
  • aCH+/ε4+个体相对aCH-/ε4-的MCI风险增加超过2倍(HR 2.69,p<0.001)。
  • aCH+/CSF+个体相对aCH-/CSF-的MCI风险增加超过4倍(HR 4.89,p<0.001)。
  • aCH预测记忆下降斜率更陡(t=-2.35,p=0.02)和语言下降斜率更陡(t=-2.35,p=0.02),AD风险因素者效应加剧。

临床怎么用

  • 对认知正常老年人,尤其具有APOE ε4或CSF AD病理者,应评估抗胆碱能药物使用并考虑减处方。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the cognitive consequences of anticholinergic medications (aCH) in cognitively normal older adults as well as interactive effects of genetic and CSF Alzheimer disease (AD) risk factors. METHODS: A total of 688 cognitively normal participants from the Alzheimer's Disease Neuroimaging Initiative were evaluated (mean age 73.5 years, 49.6% female). Cox regression examined risk of progression to mild cognitive impairment (MCI) over a 10-year period and linear mixed effects models examined 3-year rates of decline in memory, executive function, and language as a function of aCH. Interactions with APOE ε4 genotype and CSF biomarker evidence of AD pathology were also assessed. RESULTS: aCH+ participants had increased risk of progression to MCI (hazard ratio [HR] 1.47, p = 0.02), and there was a significant aCH × AD risk interaction such that aCH+/ε4+ individuals showed greater than 2-fold increased risk (HR 2.69, p < 0.001) for incident MCI relative to aCH-/ε4-), while aCH+/CSF+) individuals demonstrated greater than 4-fold (HR 4.89, p < 0.001) increased risk relative to aCH-/CSF-. Linear mixed effects models revealed that aCH predicted a steeper slope of decline in memory (t = -2.35, p = 0.02) and language (t = -2.35, p = 0.02), with effects exacerbated in individuals with AD risk factors. CONCLUSIONS: aCH increased risk of incident MCI and cognitive decline, and effects were significantly enhanced among individuals with genetic risk factors and CSF-based AD pathophysiologic markers. Findings underscore the adverse impact of aCH medications on cognition and the need for deprescribing trials, particularly among individuals with elevated risk for AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Weigand AJ, Bondi MW, Thomas KR, et al. Association of anticholinergic medications and AD biomarkers with incidence of MCI among cognitively normal older adults. Neurology. 2020. PMID: 32878992. doi:10.1212/WNL.0000000000010643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。